• Home>
  • Stocks>
  • Alembic Pharmaceuticals Ltd Share Price
Alembic Pharmaceuticals Ltd share price logo

Alembic Pharmaceuticals Ltd Share Price

(APLLTD)

Small Cap

Healthcare Sector

Check the latest share price of Alembic Pharmaceuticals Ltd, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.

₹879.8

▲1.05%

as on 04:01PM, 29 Apr 2025

NSE

bell
The current prices are delayed by 15 mins, login to check live prices.

Alembic Pharmaceuticals Ltd Performance

Get real-time share price information, day’s high and low, historical returns and market stats.

  • Day's Low

    Day's High

    ₹870.7
    Day's Price Range
    ₹885.65

  • 52 Week's Low

    52 Week's High

    ₹725.2
    52-Week Price Range
    ₹1,303.9
1 Month Return+ 2.97 %
3 Month Return-15.53 %
1 Year Return-12.61 %
Previous Close₹870.70
Open₹870.70
Volume95.96K
Upper Circuit-
Lower Circuit-
Market Cap₹16,637.10Cr

Alembic Pharmaceuticals Ltd Fundamentals & Key Indicators

Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.

Market Cap

₹16,637.10 Cr

Return on Equity (ROE)

10.46

Return on capital employed (ROCE)

11.38

P/B Ratio

2.75

Dividend Yield

1.35

EPS (TTM)

26.24

Sector

Pharmaceuticals

How to invest in Alembic Pharmaceuticals Ltd

Investing in Alembic Pharmaceuticals Ltd is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Alembic Pharmaceuticals Ltd or APLLTD on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

For example: You can buy 10 shares of Alembic Pharmaceuticals Ltd or start an SIP based on the market price on each investment date.

You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Alembic Pharmaceuticals Ltd with just a few clicks!

Alembic Pharmaceuticals Ltd Valuation

Track how the P/E of Alembic Pharmaceuticals Ltd has moved over time to understand valuation trends.

Alembic Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (11.53x)

March 23, 2020

Today (28.36x)

December 15, 2023

Industry (58.33x)

December 15, 2023

Highest (53.41x)

January 3, 2023

LowHigh

Today’s Price to Earnings Ratio: 28.36x

Analysts Recommendation on Alembic Pharmaceuticals Ltd

Get updated buy, sell, and hold recommendations by analysts on Alembic Pharmaceuticals Ltd.

based on 15 analysts

HOLD

26.67%

Buy

40.00%

Hold

33.33%

Sell

40% of analysts recommend a 'HOLD' rating for Alembic Pharmaceuticals Ltd. Average target of ₹717

Source: S&P Global Market Intelligence

Analysts Forecast on Alembic Pharmaceuticals Ltd

Get share price movements and forecasts by analysts on Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd price forecast by 15 analysts

Downside of-15.29%

High

₹895

Target

₹717.00

Low

₹515

Alembic Pharmaceuticals Ltd target price ₹717, a slight downside of -15.29% compared to current price of ₹879.8. According to 15 analysts rating.

Source: S&P Global Market Intelligence

Alembic Pharmaceuticals Ltd Financials

Get the annual and quarterly financial summary of Alembic Pharmaceuticals Ltd, including revenue, profit, loss and more.

Value in ₹ crore
DetailsQ'2 23Q'3 23Q'4 23Q'1 24Q'2 24
Revenue₹1,486.15Cr (-)₹1,594.93Cr (↑7.32%)₹1,630.57Cr (↑2.23%)₹1,516.98Cr (↓6.97%)₹1,561.73Cr (↑2.95%)
Net Income₹120.60Cr (-)₹136.56Cr (↑13.23%)₹180.45Cr (↑32.14%)₹178.21Cr (↓1.24%)₹134.54Cr (↓24.50%)
Net Profit Margin8.11% (-)8.56% (↑5.55%)11.07% (↑29.32%)11.75% (↑6.14%)8.61% (↓26.72%)
Value in ₹ crore
Details2019202020212022
Total Assets₹4,644.65Cr (-)₹5,993.26Cr (↑29.04%)₹6,786.27Cr (↑13.23%)₹7,225.34Cr (↑6.47%)
Total Liabilities₹1,932.24Cr (-)₹2,647.25Cr (↑37.00%)₹1,684.46Cr (↓36.37%)₹1,935.00Cr (↑14.87%)
Value in ₹ crore
Details20182019202020212022
Operating Cash Flow₹304.55Cr (-)₹808.79Cr (↑165.57%)₹539.75Cr (↓33.26%)₹1,388.48Cr (↑157.25%)₹545.26Cr (↓60.73%)

Alembic Pharmaceuticals Ltd Index Inclusions

BSE 500

₹34,765.79

0 (▲0%)

Nifty Smallcap 250

₹15,639.70

0.21 (▲32.55%)

Nifty 500

₹0.00

0 (▲0%)

BSE Healthcare

₹42,555.65

0 (▲0%)

BSE Small-Cap

₹48,193.46

0 (▲0%)

S&P BSE 250 SmallCap

₹6,257.98

0 (▲0%)

S&P BSE 400 MidSmallCap

₹11,171.57

0 (▲0%)

Nifty MidSmallcap 400

₹18,431.30

0.21 (▲38.8%)

S&P BSE AllCap

₹10,471.31

0 (▲0%)

Alembic Pharmaceuticals Ltd Shareholding Pattern

View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Alembic Pharmaceuticals Ltd.

InvestorsHoldings %Quarterly Trend3M change
Promoter Holdings
69.61%
0.00
Foreign Institutions
4.55%
0.00
Mutual Funds
6.47%
0.00
Retail Investors
12.53%
0.00
Others
6.84%
0.00

Alembic Pharmaceuticals Ltd vs Peers

Compare market cap, revenue, PE, and other key metrics of Alembic Pharmaceuticals Ltd with its industry peers.

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd
HOLD₹16,637.10 Cr6.43%0.57NANA
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
BUY₹63,424.92 Cr22.06%0.55NANA
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
BUY₹87,426.64 Cr31.24%0.59NANA
Glaxosmithkline Pharmaceuticals Ltd
Glaxosmithkline Pharmaceuticals Ltd
HOLD₹46,605.29 Cr17.26%0.55NANA
Syngene International Ltd
Syngene International Ltd
BUY₹28,250.05 Cr30.32%0.64NANA
See all

Alembic Pharmaceuticals Ltd News & Key Events

Latest news and events at one place to help you take investing decisions in Alembic Pharmaceuticals Ltd.

  • Alembic Pharma Secures USFDA Approval for Carbamazepine - 17 Apr, 2025

    Alembic Pharmaceuticals has received final USFDA approval for Carbamazepine Tablets USP, 200 mg, which are therapeutically equivalent to Novartis' Tegretol. The estimated market size is $32 million for the next year.

  • Alembic Pharma Secures USFDA Approval for Injection - 01 Apr, 2025

    Alembic Pharmaceuticals has received USFDA approval for Pantoprazole Sodium for Injection, a significant addition to its portfolio, bringing total ANDA approvals to 221. The estimated market size for this product is $48 million for the year ending December 2024.

  • Alembic Partners with Amlan for Poultry Solutions - 25 Mar, 2025

    Alembic Pharmaceuticals has entered a strategic agreement with Amlan International to introduce advanced poultry health solutions in India, enhancing productivity and sustainability in the sector.

  • Alembic Pharma's API Facility Passes USFDA Inspection - 22 Mar, 2025

    Alembic Pharmaceuticals announced the successful completion of a USFDA inspection at its API-III facility in Karakhadi, Gujarat, with zero observations. This achievement reinforces the company's commitment to quality and regulatory compliance, enhancing its reputation in the global market.

Insights on Alembic Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, APLLTD stock has moved up by 1.7%

  • imgPOSITIVE IMPACT

    Promoter Holding Up

    img

    Promoters have increased holdings from 69.61% to 69.67% in Mar 2025 quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 8.96% to 9.20% in Mar 2025 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 1.52K Cr → 1.70K Cr (in ₹), with an average increase of 3.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 63.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 125.5%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 4.17% to 3.94% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 10.16% to 9.96% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 153.41 Cr → 138.42 Cr (in ₹), with an average decrease of 9.8% per quarter

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals is a leading generic pharmaceuticals manufacturer and marketer based in India. Established in 2010 as a subsidiary of Alembic Ltd., they stopped being a subsidiary in 2011 when they were allotted 133515914 equity shares of Rs 2 each to their shareholders. In 2014 Alembic Pharmaceuticals entered into a joint venture with Adwiya Mami SARL, Algeria and in 2015 an exclusive agreement was signed with Novartis. In 2016, Alembic Pharmaceuticals formed Aleor Dermaceuitical Limited in a 60:40 joint venture with Orbicular and a state-of-the-art anticancer manufacturing facility opened in Gujarat in 2017. One year later Alembic Pharmaceuticals completed the acquisition of Orit Laboratories LLC, a generic drug developer, along with real estate. In 2018 Alembic Pharmaceuticals was inspected by the US FDA and were issued with 3 observations. In 2019, they launched 9 new products in the US, and the novel Umbralicib UKONIQ was licensed by TG Therapeutics USA in 2021. In 2022, Aleor Dermaceuticals was amalgamated into Alembic Pharmaceutical and became a wholly owned subsidiary.

Revenue: ₹1,561.73Cr as on June 2024 (Q2 24)
Net Profit: ₹134.54Cr as on June 2024 (Q2 24)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
OrganisationAlembic Pharmaceuticals Ltd
HeadquartersVadodara
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Indian Mutual Funds that own Alembic Pharmaceuticals Ltd

Check out the Mutual Funds with significant holdings in Alembic Pharmaceuticals Ltd.

Futures and Options

View the latest movement in Alembic Pharmaceuticals Ltd Futures & Options, including strike prices, expiry dates, and percentage changes.

FAQs

What is Alembic Pharmaceuticals Ltd price today?

Alembic Pharmaceuticals Ltd share price today stands at ₹879.8, Open: ₹870.7, Previous Close: ₹870.7, High: ₹885.65, Low: ₹870.7, 52 Week High: ₹1303.9, 52 Week Low: ₹725.2.

How to Buy Alembic Pharmaceuticals Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Alembic Pharmaceuticals Ltd shares

What are today's traded volumes of Alembic Pharmaceuticals Ltd?

Today's traded volume of Alembic Pharmaceuticals Ltd(APLLTD) is 95.96K.

What is today's market capitalisation of Alembic Pharmaceuticals Ltd?

Today's market capitalisation of Alembic Pharmaceuticals Ltd(APLLTD) is ₹16,637.10 Cr.

What is the 52 Week High and Low Range of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd (APLLTD)
Price
52 Week High
₹1303.9
52 Week Low
₹725.2

How much percentage Alembic Pharmaceuticals Ltd is down from its 52 Week High?

Alembic Pharmaceuticals Ltd (APLLTD) share price is ₹879.8. It is down -32.53% from its 52 Week High price of ₹1303.9

How much percentage Alembic Pharmaceuticals Ltd is up from its 52 Week low?

Alembic Pharmaceuticals Ltd (APLLTD) share price is ₹879.8. It is up 21.32% from its 52 Week Low price of ₹725.2